Vitiligo
Conditions
Brief summary
The purpose of this research is to treat vitiligo with a topical PGF2α, microneedling and excimer laser. The goal is to have greater repigmentation than the standard of care (excimer) after 12 weeks of treatment. The study is a pilot, split study meaning the patient will receive one experimental and one standard of care treatment on symmetric lesions of similar location, geometrics and size. Enrolled subjects will present biweekly to clinic on the same two days for twelve weeks. One lesion will be treated with microneedling, topical PGF2α and calibrated excimer laser, while the parallel lesion will be excimer laser alone. Physical exam, photographs, and a review of of the subjects medical records will occur in the study. Changes in size, appearance, and adverse events will be monitored throughout the study. The patient will also agree to close up photographs of their lesions throughout the study. The possible benefit of joining this study is that the treatment received may be more effective than the other study treatment or then other available treatments for vitiligo, although this cannot be guaranteed.
Interventions
DRUGBimatoprost
Participants will be receiving 2 drops per 4cm2 twice a week for 12 weeks
DEVICEExcimer laser
Participants will be receiving excimer laser 2x a week for 12 weeks
DEVICEMicroneedling with a dermaroller
Participants will have 4cm2 area pre-treated with dermaroller 2x per week for 12 weeks
Sponsors
Medical University of South Carolina
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* All patients 18 years and older with the diagnosis of Vitiligo.
Exclusion criteria
* Female patients currently pregnant or lactating * Female patients with plans to come pregnant during the next 3 months * Allergic reactions to topical or oral prostaglandins * Uncontrolled skin disease * History of glaucoma * Concomitant disease or therapy that interferes with the diagnosis that might interfere with vitiligo diagnosis sand evaluation. * Patients currently using other treatments for Vitiligo, such as topical steroids, calcineurin inhibitors, and Vitamin D analogs within 2 weeks of study initiation * Inability or unwillingness of subject or legal guardian/representative to give
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of skin repigmentation after 12 weeks | Post treatment (at week 12) | A blinded outcome accessor will compare photographs of patients before and after treatment. |
| Number of patients with perceived improvement after 12 weeks. | Week 12 | Patients will be completing the Vitiligo Noticeability Scale that encompasses a series of questions assessing patient perceived change of before and after photographs. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in quality of life | Baseline and post treatment approximately 12 weeks | To access vitiligo patient specifically though a QOL reliable and valid scale. |
Countries
United States
Outcome results
None listed